Harada T, Mayberg M R
Department of Neurological Surgery, University of Washington, Seattle.
J Neurosurg. 1992 Nov;77(5):763-7. doi: 10.3171/jns.1992.77.5.0763.
The potential role of iron in cerebral vasospasm was examined in the rat femoral artery model by the perivascular application of deferoxamine, a ferric ion chelator and antioxidant. In 25 rats, platelet-rich plasma or fresh autologous whole blood containing deferoxamine at concentrations of 1, 5, 10, or 15 mg/ml was applied to the adventitial surface of the femoral artery in a Silastic cuff to insure chronic exposure to the vessel wall. At 7 days, contralateral femoral arteries exposed to whole blood showed a 70% reduction in luminal cross-sectional area and morphological changes associated with vasospasm. Application of platelet-rich plasma or whole blood containing deferoxamine at 25 mg/ml produced no significant arterial narrowing or structural changes; significant intermediate reductions in arterial narrowing were observed at deferoxamine concentrations of 5 and 10 mg/ml. Presaturation deferoxamine (10 mg/ml) with excess ferric ion prior to application eliminated the protective effect. In addition, deferoxamine chelated the ferric ion released from incubated whole blood in vitro over 7 days in a dose-dependent manner consistent with its protective effect in vivo. Ferric ion may influence the development of chronic arterial narrowing after subarachnoid hemorrhage by a variety of mechanisms.
通过在大鼠股动脉模型中血管周围应用去铁胺（一种铁离子螯合剂和抗氧化剂），研究了铁在脑血管痉挛中的潜在作用。在25只大鼠中，将含有浓度为1、5、10或15mg/ml去铁胺的富血小板血浆或新鲜自体全血应用于置于硅橡胶套管中的股动脉外膜表面，以确保血管壁长期暴露于其中。7天时，暴露于全血的对侧股动脉管腔横截面积减少70%，并出现与血管痉挛相关的形态学变化。应用含有25mg/ml去铁胺的富血小板血浆或全血未产生明显的动脉狭窄或结构变化；在去铁胺浓度为5和10mg/ml时，观察到动脉狭窄有明显的中度减轻。应用前用过量铁离子预饱和去铁胺（10mg/ml）消除了保护作用。此外，去铁胺在体外7天内以剂量依赖方式螯合了从孵育的全血中释放的铁离子，这与其在体内的保护作用一致。铁离子可能通过多种机制影响蛛网膜下腔出血后慢性动脉狭窄的发展。
